Abstract Library

#3077 Insights into the Practice Patterns, Challenges and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients in the Community

Introduction: Management of NET patients often involves a multidisciplinary approach,requiring collaboration between referring oncologists,surgeons,endocrinologists locally and NET specialty centers (NSC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yelamanchili R

Authors: Radhika Y, Chan D, Thawer A, Lo D, Singh S,

Keywords: Shared care, NET, Local Medical Oncologists, NET specialty centers,

#2928 Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumour (NET) Patients (SCAN) – Assessment of Early Diagnosis

Introduction: SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Van Genechten D

Authors: Van Genechten D, McDonnell M, Rodien-Louw C, Dureja S, Leyden S,

Keywords: Neuroendocrine Tumours, Survey, Earlier diagnosis,

#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile

Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carrillo D

Authors: Carrillo D, Munoz-Anguita G, Madison A, Retamal I, Pinto M,

Keywords: Neuroendocrine, Carcinoid, Health-related quality of life.,

#2796 Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey

Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Levy S

Authors: Levy S, Aarts M, Eskens F, Keymeulen K, Been L,

Keywords: Merkel Cell Carcinoma, Avelumab, PD-L1,

#2789 The Patient Journey – Experience from Symptoms to Diagnosis among Patients with Small Intestinal Neuroendocrine Tumours (SINET)

Introduction: Patients with SINET often have diffuse symptoms delaying diagnosis. In a patient survey it was observed that 1/3 of NET patients had a time span to diagnosis of > 5 years, with a median of 52 months. Here we assess the patients’ experience during that time period.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Holgersson K

Authors: Holgersson K, Ståhl E, Nilsson M, Grauers B, Mårtensson-Djäken E,

Keywords: SINET, patients' experience, interview,